| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $194.0M | — | -4.4% |
| R&D Expense | $30.2M | — | -3.1% |
| SG&A Expense | $26.8M | — | -9.5% |
| Operating Income | $14.0M | — | -40.1% |
| Pre-tax Income | $5.6M | — | -66.2% |
| Income Tax | $4.5M | — | -20.4% |
| Net Income | $1.2M | — | -89.4% |
| EPS (Basic) | $0.00 | — | -100.0% |
| EPS (Diluted) | $0.00 | — | -100.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $235.7M | -10.0% | -21.7% |
| Accounts Receivable | $232.7M | -1.3% | +45.3% |
| Current Assets | $1.27B | +96.9% | +134.4% |
| Total Assets | $2.02B | +44.0% | +56.0% |
| Current Liabilities | $859.2M | +249.3% | +731.1% |
| Long-term Debt | $482.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $11.8M | — | +25.8% |
| Capital Expenditures | $1.1M | — | +700.0% |
| Investing Cash Flow | -$21.6M | — | +58.3% |
| Financing Cash Flow | -$16.3M | — | +84.5% |
| Free Cash Flow | $10.7M | — | +15.4% |
| -0.7% |
| Total Liabilities | $1.40B | +77.6% | +118.3% |
| Stockholders' Equity | $622.0M | +0.9% | -4.9% |